Exopolysaccharides (EPSs), major components of the bacterial biofilm, display strong strain-specific immunomodulatory properties. Previously, we have shown that crude EPS derived from Lactobacillus rhamnosus KL37 depresses the production of arthritogenic anti-collagen IgG and ameliorates collagen-induced arthritis (CIA) in DBA/1 mice, when lipopolysaccharide (LPS) was used as adjuvant. In this study, we used highly purified EPS from L. rhamnosus KL37 (EPS-37) to verify its anti-inflammatory properties and the ability to suppress T cell-dependent humoral response. We have employed the model of active CIA, in which mice immunized with type II collagen (CII) along with LPS were treated with pure EPS-37. Intravenous administration of purified EPS-37 markedly ameliorated arthritis and reduced CII-specific antibody production. EPS-37 injected subcutaneously reduced the clinical symptoms of CIA but without the reduction of arthritogenic antibodies. In addition, the effect of EPS-37 on T-cell functions was tested ex vivo and in vitro. EPS-37 inhibited the in vitro proliferation of T cells activated both in vivo (CII immunization) and in vitro (antigen/mitogen), and markedly reduced the production of interferon (IFN)-γ. These results together with other reports suggest that anti-inflammatory potential of EPS-37 depends on its ability to inhibit either one or the other or both possible inflammatory signaling pathways. Namely, Th1 → IFN-γ → M1 inflammatory macrophages → arthritis and/or Th1 → IFN-γ → B cells → arthritogenic antibodies → arthritis. We suggest that L. rhamnosus KL37 EPS might be utilized to control T cell-dependent immune responses in various inflammatory diseases. However, the most effective route of EPS-37 administration needs to be tailored for a given disorder.

中文翻译：

---

来自鼠李糖乳杆菌KL37的胞外多糖抑制小鼠的T细胞依赖性免疫反应。

细菌生物膜的主要成分外多糖（EPS）具有很强的菌株特异性免疫调节特性。以前，我们已经证明，当脂多糖（LPS）用作佐剂时，源自鼠李糖乳杆菌KL37的粗制EPS抑制了关节炎形成的抗胶原IgG的产生，并改善了DBA / 1小鼠的胶原诱导的关节炎（CIA）。在这项研究中，我们使用了鼠李糖乳杆菌KL37（EPS-37）的高度纯化的EPS来验证其抗炎特性和抑制T细胞依赖性体液反应的能力。我们采用了主动CIA模型，其中用II型胶原蛋白（CII）和LPS免疫的小鼠用纯EPS-37处理。静脉内注射纯化的EPS-37可明显改善关节炎，并减少CII特异性抗体的产生。皮下注射EPS-37可以减轻CIA的临床症状，但不会减少致关节炎的抗体。另外，离体和体外测试了EPS-37对T细胞功能的影响。EPS-37抑制了在体内（CII免疫）和体外（抗原/有丝分裂原）均激活的T细胞的体外增殖，并显着降低了干扰素（IFN）-γ的产生。这些结果以及其他报道表明，EPS-37的抗炎潜力取决于其抑制一个或另一个或两个可能的炎症信号通路的能力。即，Th1→IFN-γ→M1炎性巨噬细胞→关节炎和/或Th1→IFN-γ→B细胞→关节炎抗体→关节炎。我们建议L。鼠李糖KL37 EPS可能被用于控制各种炎性疾病中的T细胞依赖性免疫反应。但是，EPS-37给药的最有效途径需要针对给定的疾病进行调整。